Crucell and DSM Announce Licensing and Service Agreement with Roche for Protein Production
Roche has selected PER.C6® for this particular protein because it believes PER.C6® possesses unique features capable of delivering the appropriate product quality. Further to this agreement, Crucell will work with Roche in creating a production clone for the specific protein.
Under the terms of the agreement, Roche will pay a research license payment, annual maintenance fees, and research funding. Further financial details were not disclosed.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.